Business
Artiva Biotherapeutics Announces Upcoming Presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR® (Tandem Meetings) Highlighting Cost-Effectiveness of AlloNK in a Community Rheumatology Practice and Continued Durability of AlloNK in NHL
SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (Tandem Meetings) from February 4 – 7, 2026, in Salt Lake City, Utah highlighting the cost-effectiveness of AlloNK in a
About this update from Artiva Biotherapeutics, Inc.
[{"type":"image","alt":"Artiva Biotherapeutics, Inc.","displaySize":"","headline":null,"caption":"Artiva Biotherapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":163,"url":"https://media.zenfs.com/en/globenewswire.com/e751b0da58af1d359d964a2a78d6ca43"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/qlnfoD..J1RiP0FeWYqi_g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIyODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/e751b0da58af1d359d964a2a78d6ca43","width":300,"height":163}},"lazy":false},{"type":"text","content":"SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced presentations at the 2026 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (Tandem Meetings) from February 4 – 7, 2026, in Salt Lake City, Utah highlighting the cost-effectiveness of AlloNK in a community rheumatology practice and continued durability of AlloNK in Non-Hodgkin Lymphoma (NHL).","length":602,"tagName":"p"},{"type":"text","content":"The following abstracts will be presented as poster presentations at the 2026 Tandem Meetings:","length":94,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"style":"max-width:15%;width:15%;min-width:15%;vertical-align:top;","val":[{"type":"text","content":"Poster ID: 440","length":14,"tagName":"p","attribs":{}}]},{"style":"max-width:85%;width:85%;min-width:85%;vertical-align:top;","val":[{"type":"text","content":"AB-101, an Off-the-Shelf NK Cell Therapy Administered in an Outpatient Community Rheumatology Practice, Is More Cost-Effective Than CAR-T Treatments for Rheumatologic Diseases","length":180,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"vertical-align:top;","val":[{"type":"text","content":"Poster Session:","length":15,"tagName":"p","attribs":{}}]},{"style":"vertical-align:top;","val":[{"type":"text","content":"Health Services and Barriers to Access","length":38,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"vertical-align:top;","val":[{"type":"text","content":"Date / Time:","length":12,"tagName":"p","attribs":{}}]},{"style":"vertical-align:top;","val":[{"type":"text","content":"Thursday, February 5, 2026, at ...